Joint Pain Injections Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The market for joint pain injections is poised for significant expansion in the coming years, driven by advancements in treatment options and a growing focus on personalized patient care. This report explores the anticipated market size, key contributors, current trends, and detailed segments shaping the future of this healthcare sector.

Projected Growth and Market Size of the Joint Pain Injections Market
The joint pain injections market is expected to experience rapid growth, reaching a valuation of $10.96 billion by 2030. This expansion will occur at a compound annual growth rate (CAGR) of 12.3%. Factors fueling this rise include wider adoption of biologic therapies for pain, an increased emphasis on personalized medicine, the broadening scope of sports injury management, growing investments in regenerative medical solutions, and a heightened preference for non-opioid pain relief options. Upcoming trends likely to influence the market involve greater use of non-surgical pain therapies, increased application of hyaluronic acid and platelet-rich plasma (PRP) injections, expansion of regenerative medicine-focused injections, and a stronger concentration on outpatient pain relief strategies.

Download a free sample of the joint pain injections market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6482&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Companies Driving the Joint Pain Injections Industry
The joint pain injections market features several top-tier players, including Seikagaku Corporation, Anika Therapeutics Inc., Bioventus Inc., Flexion Therapeutics Inc., Ferring Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Limited, Wockhardt Ltd., Mallinckrodt Pharmaceuticals Ltd., Mylan N.V., Bayer AG, Eli Lilly and Company, Ipsen SA, Takeda Pharmaceutical Company Limited, and AstraZeneca plc.

Collaborative Efforts Enhancing Product Reach in Joint Pain Treatment
In July 2025, Johnson & Johnson MedTech, a US-based medical device and healthcare solutions provider, teamed up with Pacira BioSciences to broaden early intervention options for knee osteoarthritis. This collaboration aims to increase the market penetration of ZILRETTA, a triamcinolone acetonide extended-release injectable, by improving product accessibility and expanding its use in the knee osteoarthritis segment. Pacira BioSciences specializes in non-opioid pain management and local analgesic products, including intra-articular injections designed for joint pain relief.

View the full joint pain injections market report:
https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Innovations Shaping the Joint Pain Injections Market
Key players in the joint pain injections sector are investing in innovations such as single-injection formulations, which enhance patient convenience by delivering sustained therapeutic effects with just one dose. For example, in July 2024, South Korea-based LG Chem Ltd. introduced Synovian in China, a novel single-injection treatment for knee osteoarthritis. This innovative therapy, developed with proprietary technology, is the first of its kind in the country and targets a promising market estimated at roughly KRW 200 billion (around USD 150 million). The product emphasizes effective pain relief while minimizing the need for multiple administrations.

Detailed Segmentation of the Joint Pain Injections Market
This report categorizes the joint pain injections market by several key segments:
1) Injection Type: Steroid Joint Injections and Hyaluronic Acid Injections
2) Joint Type: Hip Joint, Knee and Ankle, Shoulder and Elbow, Facet Joints of the Spine, and Other Joint Types
3) Distribution Channel: Hospital Pharmacies and Retail Pharmacies

Further subcategories include:
- Steroid Joint Injections: Corticosteroid Injections and Combination Steroid Injections
- Hyaluronic Acid Injections: Single-Dose and Multi-Dose Hyaluronic Acid Injections

This segmentation provides a comprehensive framework for understanding the diverse offerings and delivery methods within the joint pain injections market.

What's included in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.